Last reviewed · How we verify
BOL-303224-A
At a glance
| Generic name | BOL-303224-A |
|---|---|
| Also known as | ISV-403, Besifloxacin |
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis (PHASE3)
- A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. (PHASE3)
- Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis (PHASE3)
- Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects (PHASE1)
- Systemic Pharmacokinetics of BOL-303224-A (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BOL-303224-A CI brief — competitive landscape report
- BOL-303224-A updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI